ASIRI SURGICAL HOSPITAL PLC
INTERIM FINANCIAL STATEMENT FOR THE PERIOD ENDED 30 June 2026

Asiri Surgical Hospital PLC

STATEMENT OF PROFIT OR LOSS

For the Period Ended 30 June 2026

	Group		Company	
	2026	2025	2026	2025
	Rs. Un-audited	Rs. Un-audited	Rs. Un-audited	Rs. Un-audited
Revenue	2,040,016,231	1,899,520,131	1,868,739,278	1,712,119,221
Cost of Services	(1,159,313,464)	(1,078,299,797)	(1,080,943,716)	(1,001,528,964)
Gross Profit	880,702,767	821,220,335	787,795,562	710,590,257
Other Income	17,796,407	20,039,240	30,682,680	32,625,234
Administrative Expenses	(560,044,517)	(461,504,839)	(548,452,872)	(450,702,044)
Selling and Distribution Costs	(57,445,124)	(51,956,606)	(51,760,429)	(45,756,236)
Finance Cost	(73,213,649)	(68,929,870)	(89,842,390)	(80,204,697)
Finance Income	165,891,230	98,656,654	165,277,731	98,642,444
Profit Before Tax	373,687,114	357,524,914	293,700,282	265,194,957
Tax Expense	(148,028,819)	(155,240,064)	(132,960,485)	(125,342,755)
Profit for the Period	225,658,295	202,284,850	160,739,797	139,852,203
Attributable to:				
Equity holders of the parent	194,440,890	169,963,365		
Non-controlling interest	31,217,405	32,321,485		
Earnings Per Share - Basic	0.37	0.32	0.30	0.26
Dividend Per Share	0.00	0.00	0.00	0.00

Asiri Surgical Hospital PLC

STATEMENT OF COMPREHENSIVE INCOME

For the Period Ended 30 June 2026

	Group		Company	
	2026	2025	2026	2025
	Rs. Un-audited	Rs. Un-audited	Rs. Un-audited	Rs. Un-audited
Profit for the Period	225,658,295	202,284,850	160,739,797	139,852,203
Other Comprehensive Income/(Loss)				
Other Comprehensive Income/(Loss) not to be reclassified to profit or loss in subsequent periods (net of tax) :				
Revaluation surplus on building	-	-	-	-
Actuarial gain/(loss) on retirement benefit liability	-	-	-	-
Net (Gain/Loss) an investment Subsidiary at FVOCI	-	-	-	-
Net (Gain/Loss) an Equity instrument Subsidiary at FVOCI	-	-	-	-
	-	-	-	-
Deferred Tax on Other Comprehensive Income	-	-	-	-
Net Other Comprehensive Income that will not to be reclassified to profit or loss in subsequent periods (net of tax)	-	-	-	-
Other Comprehensive Income for the period, net of tax	-	-	-	-
Total Comprehensive Income for the period, net of tax	225,658,295	202,284,850	160,739,797	139,852,203
Total Comprehensive Income Attributable to:				
Equity holders of the parent company	194,440,890	169,963,365		
Non-controlling interest	31,217,405	32,321,485		

STATEMENT OF FINANCIAL POSITION

Group			Group		Company	
As at 31-Mar-26 Rs. Un-audited	Company As at 31-Mar-26 Rs. Un-audited		As at 30-Jun-26 Rs. Un-audited	As at 30-Jun-25 Rs. Un-audited	As at 30-Jun-26 Rs. Un-audited	As at 30-Jun-25 Rs. Un-audited
		ASSETS				
		Non-current Assets				
5,636,312,460	5,257,879,043	Property, Plant and Equipment	5,674,638,228	5,437,112,054	5,302,642,914	5,072,297,150
23,386,316	23,386,316	Right-of-use Asset	23,327,730	16,993,899	23,327,730	16,993,899
-	226,400,000	Investment property	-	-	226,400,000	226,400,000
-	1,881,194,730	Investment in Subsidiary	-	-	1,881,194,729	1,881,194,730
1,979,529,017	1,979,529,017	Loans Granted to Related Parties	1,979,529,017	1,979,529,017	1,979,529,017	1,979,529,017
25,982,000	25,982,000	Non Current Assets	25,982,000	25,982,000	25,982,000	25,982,000
7,665,209,793	**9,394,371,106**		**7,703,476,975**	**7,459,616,971**	**9,439,076,390**	**9,202,396,796**
		Current Assets				
206,894,718	203,099,130	Inventories	204,691,822	138,499,199	200,104,401	135,850,496
1,614,664,951	1,677,072,457	Trade and Other Receivables	1,890,132,303	1,753,382,220	1,862,211,691	1,588,889,556
1,771,404,103	1,771,404,103	Other Current Assets	2,091,962,882	1,816,957,145	2,091,962,882	1,816,957,145
4,100,477,835	4,100,477,835	Loans Granted to Related Parties	4,188,215,726	3,827,667,429	4,188,215,726	3,827,667,429
651,235,571	150,601,651	Cash and Cash Equivalents	547,317,661	528,742,083	196,369,691	211,747,378
8,344,677,179	**7,902,655,177**		**8,922,320,392**	**8,065,248,078**	**8,538,864,389**	**7,581,112,005**
16,009,886,971	**17,297,026,283**	**Total Assets**	**16,625,797,368**	**15,524,865,049**	**17,977,940,780**	**16,783,508,800**
		EQUITY AND LIABILITIES				
1,393,327,565	1,393,327,565	Stated Capital	1,393,327,565	1,393,327,565	1,393,327,565	1,393,327,565
2,633,391,827	3,905,525,939	Other Components of Equity	2,633,391,826	2,633,391,827	3,905,525,939	3,905,525,940
3,170,616,485	2,714,358,610	Retained Earnings	3,365,057,380	2,618,310,415	2,875,098,408	2,230,568,920
7,197,335,877	**8,013,212,115**	**Share Holders' Fund**	**7,391,776,771**	**6,645,029,806**	**8,173,951,912**	**7,529,422,425**
572,095,298	-	Non-Controlling Interests	603,312,703	451,385,965	-	-
7,769,431,176	**8,013,212,115**	**Total Equity**	**7,995,089,474**	**7,096,415,770**	**8,173,951,912**	**7,529,422,425**
		Non-current Liabilities				
25,586,481	25,586,481	Lease Liability	25,586,481	25,649,000	25,586,481	25,649,000
191,385,324	191,385,324	Interest Bearing Loans and Borrowings	219,723,143	426,382,413	219,723,143	426,382,413
240,005,494	231,828,161	Employee Benefit Liability	244,591,916	181,961,599	235,960,833	175,826,325
1,249,040,914	1,771,780,071	Deferred Tax Liability	1,238,577,226	1,257,039,477	1,771,780,070	1,771,780,070
1,706,018,213	**2,220,580,038**		**1,728,478,765**	**1,891,032,488**	**2,253,050,527**	**2,399,637,808**
		Current Liabilities				
3,041,775,684	3,030,083,453	Trade and Other Payables	3,510,113,552	2,833,406,820	3,377,151,859	2,644,308,836
14,309,425	14,309,425	Dividend Payable	14,309,425	14,401,470	14,309,425	14,401,472
11,880,810	11,880,810	Lease Liability	12,785,910	5,420,400	12,785,910	5,420,400
1,646,059,137	1,646,001,314	Interest Bearing Loans and Borrowings	1,764,900,792	1,799,264,963	1,764,900,791	1,799,264,963
-	596,700,000	Loan Due to Related Party	-	-	863,356,326	608,013,103
966,161,829	910,008,428	Income Tax Payable	1,012,329,714	903,719,903	930,644,292	801,836,560
854,250,699	854,250,699	Bank Overdraft	587,789,739	981,203,236	587,789,739	981,203,236
6,534,437,583	**7,063,234,130**		**6,902,229,130**	**6,537,416,791**	**7,550,938,342**	**6,854,448,570**
16,009,886,971	**17,297,026,283**	**Total Equity and Liabilities**	**16,625,797,368**	**15,524,865,049**	**17,977,940,780**	**16,783,508,800**
14.70	15.16	Net Assets Per Share	15.13	12.57	15.47	14.25

Sgd
Mr. S.L.R Piyal
Director Finance

Sgd
Mr. Ashok Pathirage
Chairman / Managing Director

Sgd
Mr. Haresh Kaimal
Director

05th August 2026
Colombo

STATEMENT OF CHANGES IN EQUITY

For the Period Ended 30 June 2026

Group

	Attributable to equity holders of parent					Non - Controlling Interest	Total Equity
	Stated Capital Rs.	FV Reserves of Financial Assets at FVOCI Rs.	Revaluation Reserves Rs.	Retained Earnings Rs.	Total Rs.	Rs.	Rs.
Balance as at 01st April 2025	1,393,327,565	-	2,633,391,827	2,446,864,512	6,473,583,904	418,760,302	6,892,344,205
Profit for the Period	-	-	-	171,445,903	171,445,903	32,625,663	204,071,566
Other comprehensive Income	-	-	-	-	-	-	-
Total Comprehensive Income	-	-	-	171,445,903	171,445,903	32,625,663	204,071,566
Interim Dividend Paid - Ordinary Shares	-	-	-	-	-	-	-
Transfer to Retained Earnings	-	-	-	-	-	-	-
Balance as at 30th June 2025	**1,393,327,565**	-	**2,633,391,827**	**2,618,310,415**	**6,645,029,807**	**451,385,965**	**7,096,415,770**
Balance as at 01st April 2026	1,393,327,565	-	2,633,391,827	3,170,616,485	7,197,335,877	572,095,298	7,769,431,176
Profit for the Period	-	-	-	194,440,890	194,440,890	31,217,405	225,658,295
Other comprehensive Income	-	-	-	-	-	-	-
Total Comprehensive Income	-	-	-	194,440,890	194,440,890	31,217,405	225,658,295
Balance as at 30th June 2026	**1,393,327,565**	-	**2,633,391,826**	**3,365,057,380**	**7,391,776,769**	**603,312,703**	**7,995,089,474**

Company

	Stated Capital Rs.	FV Reserves of Financial Assets at FVOCI Rs.	Revaluation Reserves Rs.	Retained Earnings Rs.	Total Equity Rs.
Balance as at 01st April 2025	1,393,327,565	1,293,176,237	2,612,349,702	2,087,751,554	7,386,605,060
Profit for the Period	-	-	-	142,817,366	142,817,366
Other comprehensive Income	-	-	-	-	-
Total Comprehensive Income	-	-	-	142,817,366	142,817,366
Balance as at 30th June 2025	**1,393,327,565**	**1,293,176,237**	**2,612,349,702**	**2,230,568,921**	**7,529,422,425**
Balance as at 01st April 2026	**1,393,327,565**	**1,293,176,237**	**2,612,349,702**	**2,714,358,610**	**8,013,212,115**
Profit for the Period	-	-	-	160,739,797	160,739,797
Other comprehensive Income	-	-	-	-	-
Total Comprehensive Income	-	-	-	160,739,797	160,739,797
Balance as at 30th June 2026	**1,393,327,565**	**1,293,176,237**	**2,612,349,702**	**2,875,098,408**	**8,173,951,912**

STATEMENT OF CASH FLOWS

For the Period Ended 30 June 2026

	Group		Company	
	2026	2025	2026	2025
Cash Flows From Operating Activities	Rs.	Rs.	Rs.	Rs.
Profit Before Income Tax Expense	373,687,114	357,524,914	293,700,282	265,194,957
Adjustments for				
Amortization of Right of use Asset	58,586	74,094	58,586	74,094
Depreciation	107,671,181	101,645,268	97,147,837	90,542,358
Loss on Sale of Property, Plant and Equipment	-	-	-	-
Finance Income	(165,891,230)	(98,656,654)	(166,463,150)	(98,642,444)
Finance Expense	73,213,649	68,929,870	89,842,390	80,204,697
Unrealized Foreign Currency Exchange Gain	2,720,819	347,207	2,720,819	347,207
Provision for Retirement Obligation Plan	12,287,040	11,231,749	11,833,290	10,956,749
Provision for Bad Debts	1,091,603	4,323,388	1,091,603	4,323,388
Inventory Write off	-	233,362	-	233,362
Rou Liability reassement Loss	-	-	-	-
Impairment of loans & Other receivables	-	-	-	-
Scrip dividends received	-	-	-	-
Change in Fair Value of Investment Property	-	-	-	-
Operating Profit Before Working Capital Changes	404,838,762	445,653,197	329,931,657	353,234,369
Changes in Working Capital				
(Increase)/Decrease in Inventories	2,202,896	883,674	2,994,729	386,769
(Increase)/Decrease in Trade and Other Receivables	(276,558,954)	(505,513,861)	(186,230,836)	(494,333,209)
(Increase)/Decrease in Other Current Assets	(268,754,650)	(493,084,174)	(268,754,650)	(467,731,482)
Increase/(Decrease) in Trade and Other Payables	484,994,194	484,983,167	347,068,405	386,774,101
(Increase)/Decrease Amounts Due from Related Parties	6,604,758	-	6,604,758	-
Increase/(Decrease) Amounts Due to Related Parties	-	-	16,656,326	-
(Increase)/Decrease Amounts Due from Related Parties	-	-	-	-
Increase/(Decrease) Amounts Due to Related Parties				
	(51,511,755)	(512,731,194)	(81,661,267)	(574,903,821)
Cash Generated From Operations	353,327,007	(67,077,997)	248,270,390	(221,669,452)
Income Tax paid	(112,641,194)	(72,600,496)	(112,684,322)	(72,600,496)
Finance Costs paid	(77,525,839)	(68,929,870)	(77,498,254)	(80,204,697)
Defined Benefit Plan Costs paid	(7,700,617)	(14,281,657)	(7,700,617)	(14,139,757)
Net Cash Flows From Operating Activities	155,459,356	(222,890,020)	50,387,196	(388,614,403)
Cash Flows From/(Used in) Investing Activities				
Acquisition of Property, Plant and Equipment	(147,283,318)	(12,763,973)	(141,911,709)	(12,763,973)
Proceeds from Sale of Shares	-	-	-	-
Proceeds from Sale of Property, Plant & Equipment	-	-	-	-
Loans Granted to Related Parties	-	-	-	-
Loans Repayments from Related Parties	-	-	-	-
Investment in Financial Instruments	-	-	-	-
Finance income received	613,500	98,656,654	-	98,642,444
Loans Received from Related Parties	-	-	250,000,000	125,000,000
Net Cash Flows From Investing Activities	(146,669,818)	85,892,682	108,088,291	210,878,471
Cash Flows from /(Used in) Financing Activities				
Proceeds From Interest Bearing Loans and Borrowings	1,133,000,000	-	1,133,000,000	-
Repayment of Lease Liability	(450,000)	-	(450,000)	-
Repayment of Interest Bearing Loans and Borrowings	(978,796,489)	(174,969,587)	(978,796,489)	(174,969,587)
Dividend Paid	-	-	-	-
Net Cash Flows from Decrease Used in Financing Activities	153,753,511	(174,969,587)	153,753,512	(174,969,587)
Net Increase in Cash and Cash Equivalents	162,543,049	(311,966,924)	312,228,999	(352,705,518)
Cash and Cash Equivalents at the beginning of the year	(203,015,128)	(138,324,337)	(703,649,048)	(416,750,341)
Cash and Cash Equivalents at the end of the year	(40,472,078)	(450,291,261)	(391,420,048)	(769,455,859)
Cash & Cash Equivalents				
Cash and Bank Balances	547,317,661	522,893,031	196,369,691	203,728,434
Bank Overdrafts	(587,789,739)	(973,184,292)	(587,789,739)	(973,184,292)
	(40,472,078)	(450,291,261)	(391,420,048)	(769,455,859)

NOTES TO THE INTERIM FINANCIAL STATEMENTS

For the Period Ended 30 June 2026

1. Corporate Information

1.1 General

Asiri Surgical Hospital PLC ("Company") is a public limited liability Company, incorporated and domiciled in Sri Lanka and listed on the Colombo Stock Exchange. The registered office and principal place of business is located at No. 21, Kirimandala Mawatha, Colombo 5.

1.2 Date of Authorisation for Issue

The Interim Condensed Financial Statements of the Group and the Company for the period ended 30th June 2026 were authorised for issue by the Board of Directors on 05th August 2026.

2. Basis of Preparation

The interim condensed financial statements have been prepared in accordance with Sri Lanka Accounting Standard - LKAS 34 Interim Financial Reporting. These interim condensed financial statements should be read in conjunction with the annual financial statements for the year ended 31st March 2025. These financial statements provide the information as required in terms of Rule 7.4 of the Colombo Stock Exchange. The presentation and classification of the financial statements of the previous period have been amended, where relevant, for better presentation and to be comparable with those of the current period.

3. Accounting Policies

The same accounting policies and methods of computation as stated in the annual financial statements for the year ended 31st March 2025 are followed in the preparation of these Interim Condensed Financial Statements.

4. Other Information

4.1 Loans Granted to Related Parties

This includes loans granted to Asiri Hospital Holdings PLC, The Central Hospital Limited, Asiri Hospital Matara Pvt Ltd, Softlogic Retail Pvt Ltd, Asiri Central Hospital Limited, Softlogic Communications (Pvt) Ltd, Softlogic Brands (Pvt) Ltd and interest receivable thereon. The interest is charged at prevailing market interest rates for these loans.

4.2 Contingent Liabilities

A dispute has arisen with the Department of Inland Revenue with regard to the applicability of the income tax exemption for the years of assessment 2005/06 to 2014/15, in terms of the agreement entered between Asiri Surgical Hospital PLC and the Board of Investment of Sri Lanka (BOI) in 2000. With respect to the same we have received written notifications from the Tax Appeal Commission so far for the years of assessments from 2005/06 to 2013/14 and the company is assessing the provisioning requirement based on the applicable tax laws during that period. The Company has filed appeals against these assessments in the Court of Appeal and the cases are on going

We also have filed an appeal in the Supreme Court(vide Supreme Court Special Leave To APPEAL APP: SC/SPL/LA 69/2026] against the Judgment of the Court of Appeal dated 19th January 2026 relating to the Writ application (CA (Writ) 386/ 2016 which was filed by the Company to prevent seizure of bank accounts of the Company as part of IRD's recovery actions .

Since there are litigations, in accordance with Paragraph 92 of LKAS 37, we are unable to provide further information on this and associated risks, in order not to impair the outcome and/or prejudice the Company's position in this matter.

Other than above, there are no significant changes in the nature of the contingent liabilities and contingent assets which were disclosed in the Annual Report for the year ended 31st March 2025.

4.3 Capital Expenditure Commitments

There were no material commitments outstanding as at 30th June 2026 for future capital expenditure.

4.4 Comparative Information

Where necessary comparative figures have been reclassified to conform with the current year's presentation.

4.5 Share Capital

Issued and fully paid number of Ordinary Shares as at 30th June 2026 stands at 528,457,545.

5. Event after the balance sheet

No other events have occurred since the date of the Statement of Financial Position that necessitates adjustments to/or disclosures in the Provisional Accounts.

NOTES TO THE INTERIM FINANCIAL STATEMENTS

For the Period Ended 30 June 2026

6. Segment Information

The Senior Management Committee acts as the Chief Operating Decision Maker (CODM) and reviews the operating results of the Group's business units separately to support decisions on resource allocation and performance evaluation. Segment performance is assessed based on revenue and other income generated, measured on a basis consistent with the amounts reported in the Consolidated Financial Statements.

Based on the information presented to the CODM for these purposes, the Group has identified its reportable segments accordingly for the interim period.

- Pre Care which include OPD revenue, channeling revenue and OPD lab investigation services
- Post Care which include all IPD revenue including inpatient drugs and lab investigation
- Pharmaceutical which includes Pharmacy revenue

Segment	Group		Company	
	2026	2025	2026	2025
	Rs.	Rs.	Rs.	Rs.
Pre Care	703,562,690	686,979,339	532,285,736	499,578,429
Post Care	1,271,986,104	1,180,065,059	1,271,986,104	1,180,065,059
Pharmaceutical	64,467,437	32,475,733	64,467,437	32,475,733
	2,040,016,231	**1,899,520,131**	**1,868,739,278**	**1,712,119,221**

INVESTOR INFORMATION

Market Value of Shares

The market value of an ordinary share of Asiri Surgical Hospital PLC is as follows:

	Quarter ended 30-Jun-26	Quarter ended 30-Jun-25
- Highest Market Price – Rs.	28.10	14.30
- Lowest Market Price – Rs.	14.60	10.40
- Last Traded Price – Rs.	17.20	13.30

No of Shares Representing Stated Capital

	As at 30-Jun-26	As at 30-Jun-25
No of Ordinary Shares	528,457,545	528,457,545

* Earnings & net assets per share are based on 528,457,545 shares in issue as at 30th June 2026.

Statement of Shareholding of Directors

Name of Director	As at 30-Jun-26	As at 30-Jun-25
Mr. A. K. Pathirage	-	-
Mr. H. K. Kaimal	-	-
Mr. R. Selvaskadan	-	-
Mr. G.W.D.H.U. Gunawardena	-	-
Mr. Saar Shapira	-	-
Mr. I.M. Furkan	-	-
Mr. G.D.K.L. De Silva	-	-

Major Shareholdings

Twenty Largest Shareholders	30-Jun-26 No. of Shares	%	30-Jun-25 No. of Shares	%
Asiri Hospital Holdings PLC	354,094,329	67.01	422,555,413	79.96
Cargills Bank PLC/Asiri Hospital Holdings PLC	49,261,084	9.32		
Mr. D.K. Subasinghe / Mrs. S.N. Subasinghe	38,450,370	7.28	39,014,806	7.38
Mr. P.P. Subasinghe	7,545,542	1.43	8,162,598	1.54
Employees Trust Fund Board	2,347,341	0.44	4,418,750	0.84
Mr. M.R. Weerasinghe (Deceased)	2,000,000	0.38	2,000,000	0.38
Mr. Mohamed Hisham Jamaldeen	2,000,000	0.38		
Peoples Leasing & Finance PLC / S.P.Perera	1,989,609	0.38		
Mr. Jerome Hasitha Leanage	1,847,920	0.35		
LOLC Finance PLC/R. Magdon Ismail	1,793,673	0.34		
Mr.U. H. Palihakkara/Mrs. D.S. Palihakkara/Mr.K.D.H Palihakkara	1,352,046	0.26	1,352,046	0.26
MRS.Chandani Vishaka Ariyaratne/ MISS.B.A. Ariyaratne	1,333,333	0.25	1,333,333	0.25
Mr. Gihan Wickremasinghe	1,250,000	0.24		
Mr. M.D.N. Jayaratne	1,164,357	0.22	1,164,357	0.22
Mrs.Himali Sushama Jayaratne	1,164,356	0.22	1,164,356	0.22
J.B. COCOSHELL Pvt Limited	1,100,000	0.21	2,384,677	0.45
Mr. W.W.D.D.S. Perera	1,100,000	0.21		
HNB Investment Bank (Pvt) Ltd./ Mr. D.J.N. Hettiarachchi	900,000	0.17		
Mr. S.C. De Zoysa	884,068	0.17		
Dr. Himali Rangika Jayasekera	818,988	0.15	818,988	0.15
	472,397,016	89.39	492,051,402	93.11
Shares held by the balance shareholdings	56,060,529	10.61	36,406,143	6.89
Total Issued Shares	528,457,545	100.00	528,457,545	100.00
Public Shareholding	125,102,132	23.67	105,884,999	20.04
Total Number of Public Shareholders	4,519		3,550	

The Float- adjusted market capitalization as at 30th June 2026 is Rs. 2,151,477,495.51

The Company is in compliance with option 5 of the CSE Listing Rules 7.13.1 (i) (a) which requires 20 % minimum public holding percentage and 500 minimum public shareholders.

CORPORATE INFORMATION

Name of the Company
Asiri Surgical Hospital PLC

Registered Office
No. 21, Kirimandala Mawatha, Colombo 05, Sri Lanka. Telephone : 011 4524400
Email : info@asiri.lk
Web : www.asirihealth.com

Legal Form
A Quoted Public Company incorporated in Sri Lanka, under the Companies Act No. 17 of 1982 with limited liability.
The Company has re-registered under the Companies Act No. 07 of 2007. An undertaking approved by the Board of Investment of Sri Lanka (BOI) under the Board of Investment of Sri Lanka Law No. 4 of 1978.

Stock Exchange Listing
The Ordinary Shares of the Company are listed with the Colombo Stock Exchange.

Company Registration Number
PQ 208

Date of Incorporation
2nd March 2000

Directors
Mr. A.K. Pathirage - Chairman/Managing Director
Mr. H. K. Kaimal - Non- Independent Non- Executive
Mr. G. W.D.U.H. Gunawardena - Non - Independent Non - Executive
Mr. R. Selvaskandan - Independent Non-Executive
Mr. S. Shapira - Independent Non- Executive
Mr. M.I. Furkan - Independent Non - Executive
Mr. G.D.K.L.D. Silva - Independent Non- Executive

Auditors
Messrs Ernst & Young (Chartered Accountants) Rotunda Towers, No. 109, Galle Road, Colombo 03.

Secretaries
Messrs Softlogic Corporate Services (Pvt) Ltd. No. 14, De Fonseka Place, Colombo 05.

Stock Code
AMSL.N0000

Banks
Commercial Bank PLC
Hatton National Bank PLC
Nations Trust Bank PLC
Sampath Bank PLC
Cargills Bank Limited
National Development Bank PLC
DFCC Bank PLC

Subsidiary Companies
Asiri AOI Cancer Centre (Private) Limited
No. 21, Kirimandala Mawatha, Colombo 05, Sri Lanka

Audit Committee

Chairman
Mr. M. I. Furkan
Independent Non -executive Director, Asiri Hospital Holdings PLC

Committee Members

Mr. H K Kaimal
Non - Independent Non -executive Director, Asiri Surgical Hospital PLC

Mr. G.D.K.L.De Silva
Independent Non -executive Director, Asiri Surgical Hospital PLC

Frequency of meetings
Committee meets quarterly

Remuneration Committee

Chairman
Mr. M. I. Furkan
Independent Non -executive Director, Asiri Hospital Holdings PLC

Committee Members

Mr. H K Kaimal
Non - Independent Non -executive Director, Asiri Surgical Hospital PLC

Mr. G.D.K.L.De Silva
Independent Non -executive Director, Asiri Surgical Hospital PLC

Frequency of meetings
Committee meets once a year

Nomination and Governance Committee

Chairman
Mr. M. I. Furkan
Independent Non -executive Director, Asiri Hospital Holdings PLC

Committee Members

Mr. H K Kaimal
Non - Independent Non -executive Director, Asiri Surgical Hospital PLC

Mr. G.D.K.L.D. Silva
Independent Non -executive Director, Asiri Surgical Hospital PLC

Related Party Transactions Review Committee

Chairman
Mr. M. I. Furkan
Independent Non -executive Director, Asiri Hospital Holdings PLC

Committee Members

Mr. H K Kaimal
Non-Independent Non -executive Director, Asiri Surgical Hospital PLC

Mr. G.D.K.L.D. Silva
Independent Non -executive Director, Asiri Surgical Hospital PLC

Frequency of meetings
Committee meets quarterly